Compare
Prime Medicine, Inc. vs Ocugen, Inc. vs Zeo ScientifiX, Inc. vs CG Oncology, Inc.
| Latest fiscal year | Prime Medicine, Inc. PRME | Ocugen, Inc. OCGN | Zeo ScientifiX, Inc. ZEOX | CG Oncology, Inc. CGON |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-10-31 | 2025-12-31 |
| Revenue | $4.63M | $4.41M | $5.20M | $4.04M |
| Revenue growth (YoY) | +55.3% | +8.8% | +12.5% | +254.7% |
| Gross margin | n/a | n/a | 82.1% | n/a |
| Operating margin | n/m | n/m | -103.6% | n/m |
| Net margin | n/m | n/m | -106.2% | n/m |
| Net income | -$201.14M | -$67.85M | -$5.52M | -$161.00M |
| EPS (Diluted) | -$1.35 | n/a | -$0.86 | -$2.08 |
| Operating cash flow | -$162.56M | -$56.96M | -$718.0K | -$132.35M |
| Free cash flow | -$167.09M | -$57.15M | -$741.0K | -$132.48M |
| Cash & equivalents | $63.03M | n/a | n/a | $32.49M |
| Total assets | $342.73M | $43.52M | $1.53M | $791.59M |
| Total liabilities | $221.87M | $55.68M | $2.95M | $38.99M |
| Shareholders' equity | $120.87M | -$12.17M | -$1.42M | $752.60M |
| Return on year-end equity | -166.4% | n/a | n/a | -21.4% |
| Shares outstanding | 180.51M | 312.38M | 6.75M | 80.69M |
Revenue, most recent five fiscal years
| Fiscal year | Prime Medicine, Inc. | Ocugen, Inc. | Zeo ScientifiX, Inc. | CG Oncology, Inc. |
|---|---|---|---|---|
| Latest | $4.63M Ended 2025-12-31 | $4.41M Ended 2025-12-31 | $5.20M Ended 2025-10-31 | $4.04M Ended 2025-12-31 |
| 1 year earlier | $2.98M Ended 2024-12-31 | $4.05M Ended 2024-12-31 | $4.62M Ended 2024-10-31 | $1.14M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $6.04M Ended 2023-12-31 | $4.56M Ended 2023-10-31 | $204.0K Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2022-12-31 | $2.49M Ended 2022-12-31 | $6.49M Ended 2022-10-31 | n/a |
| 4 years earlier | $0 Ended 2021-12-31 | n/a | $5.60M Ended 2021-10-31 | n/a |